Q1 2025 saw revenue and net profit decline year-over-year, but operating cash flow improved. Major developments include a share buyback, controlling shareholder stake increase, and the acquisition of Nanyue Biopharmaceutical to expand plasma resources.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.